Personalis Expands NeXT Personal ctDNA Data Across Six Cancer Types at ASCO 2026
Event summary
- Personalis to present six clinical abstracts at ASCO 2026, including a podium presentation from the TRACERx Consortium.
- NeXT Personal test demonstrated 100% longitudinal sensitivity for recurrence in colorectal cancer and >80% landmark sensitivity as early as four weeks post-surgery.
- Data highlights single-digit parts-per-million (ppm) sensitivity in early-stage non-small cell lung cancer (NSCLC).
- New clinical evidence presented across six cancer types: colorectal, lung, melanoma, ovarian, endometrial, and renal cell cancers.
The big picture
Personalis’ presentation at ASCO 2026 underscores the growing importance of ultrasensitive ctDNA detection in precision oncology. The company’s NeXT Personal test is positioning itself as a critical tool for early recurrence identification and therapy response assessment, aligning with broader industry trends toward personalized cancer management. The expansion of clinical evidence across multiple cancer types could accelerate adoption and reinforce Personalis’ leadership in advanced genomics.
What we're watching
- Clinical Validation
- Whether the expanded clinical data will solidify NeXT Personal’s position as a benchmark for MRD testing.
- Market Adoption
- The pace at which NeXT Personal gains traction across the six cancer types presented at ASCO.
- Competitive Dynamics
- How Personalis’ ultrasensitive ctDNA detection capabilities will differentiate it from competitors in the precision oncology space.
Related topics